• letlifehappen's Avatar

    letlifehappen posted a blog post

    From: biospace.com Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer ...
    The post Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: healthline.com Researchers say the new treatment option is effective and less complex for some women with early stage breast cancer. For most women with early stage breast cancer, treatment options have been limited. Either remove the breast via mastectomy, or remove the tumor and irradiate the entire breast for weeks. But new research indicates that, for some women, a ...
    The post 5-Day Partial Irradiation Effective in Early Stage Breast Cancer appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: Celsion CORP From: globenewswire.com An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range of Solid Tumors with Multiple Localized Heating Sources Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in ...
    The post Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: PR Newswire – BRAF mutation status is an important factor when choosing a first-line therapy for patients with stage III and stage IV melanoma – The Know Now Testing Program covers cost of this genetic mutation testing The Know Now Testing Program, a Novartis initiative in collaboration with Quest Diagnostics, offers genetic mutation testing at no cost for all patients with ...
    The post Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Conversations with fellow cancer survivors inevitably lead me to think about some matter or topic that I have never contemplated before and such has recently occurred again. The topic of our medical records was raised by a colleague as she shared about how a portion of her medical history was lost when she moved and how difficult it was to ...
    The post Cancer Patients Need to Take Control of Their Health Information appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: dana-farber.org A combination of an immunotherapy drug and a DNA repair-blocking agent can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers indicates. The trial, known as TOPACIO/Keynote-162, offers compelling evidence that immunotherapies, which rarely have an impact against ovarian cancer as single ...
    The post Clinical trial underscores promise of immunotherapy, in combination with second drug, for ovarian cancer appeared first on Let Life Happen.